imusyn

imusyn has developed novel ready-to-use and self-loadable T Cell Staining Reagents generated from recombinant HLA and H2 class I proteins – Dyemer & myDyemer.

T cells play a pivotal role in immune surveillance, orchestrating responses against infections, cancer, and autoimmune disorders. imusyn’s cutting-edge reagents, Dyemer and myDyemer, empower researchers to explore T cell dynamics with precision. 

imusyn’s T cell staining reagents can expedite research across numerous scientific fields, including transplantation, autoimmunity, and immunology and play a central role in cellular therapies as their precision and reliability make them indispensable for R&D applications.

Dyemer represents a breakthrough in T cell staining. Engineered from MHC class I molecules expressed in mammalian cell culture, Dyemers ensure proper glycosylation for biological relevance. These ready-to-use T Cell Staining reagents allow the quantification and enumeration of antigen-specific CD8⁺ T cells using flow cytometry. By multimerising peptide-loaded MHC class I complexes onto fluorophore-labeled streptavidin, Dyemers enable surface staining for precise detection.

myDyemer offers flexibility by allowing researchers to load specific peptides onto pre-multimerised MHC class I molecules. The myDyemer technique provides exceptional convenience and a fast experimental setup. Generating functional staining reagents is simplified, requiring only the peptide-receptive myDyemer and a one-step peptide addition, shortening the hands-on time and reducing the chances of errors during manual preparation. This innovative technology saves valuable time whilst also enabling efficient detection and screening of diverse T cell specificities.

To verify the binding prediction of a peptide to certain HLA class I alleles, researchers can also benefit from imusyn’s Class I Peptide Binding Analysis services.

Peptide Binding Analysis Services

The imuPep Class I Peptide Binding Analysis provides a cutting-edge solution to confirm the stability of peptide/HLA class I complexes. This service enables the assessment of immunogenic peptides swiftly and accurately, utilising a comprehensive array of recombinant HLA class I alleles. 

Recent research has emphasised CD8⁺ T cells’ response to novel vaccines using peptides from in silico studies. However, the stability of the resulting peptide/HLA class I complex can remain uncertain. The complex’s stability can significantly impact peptide immunogenicity. Thus, a reliable assessment of complex stability is crucial during the early stages of developing new T cell epitopes.

imusyn has devised a novel method to load recombinant soluble HLA class I proteins with peptides. Peptide binding to HLA class I proteins is determined by Differential Scanning Fluorimetry (DSF), which measures fluorescence changes during temperature ramps. The peptide binders for a certain allotype can be ranked by their denaturation temperature (Ti), hence giving insights into the relative stability of the peptide/MHC complex. If DSF alone does not provide a conclusive result, peptide binding is confirmed by running the loaded complex on a native PAGE. 

Key advantages include access to over 60 different HLA class I allotypes, the ability for researchers to provide peptides without disclosing sequences, and a quick and reliable process.